Nouscom Raises 120 Million Euros for Cancer Interception

Company Nouscom Event Type Financing (Series D) Modality Off-the-shelf viral-vector neoantigen vaccine (adenoviral prime, MVA boost) Asset NOUS-209 Target Shared frameshift neoantigens (mismatch-repair-deficient / MSI tumors) Disease Area Lynch syndrome (cancer prevention); colorectal and other MMR-deficient cancers Summary Nouscom closed an oversubscribed EUR 120 million…